Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release its Q3 earnings later this week. Analysts are expecting strong results driven by the continued success of Lilly's blockbuster treatments, particularly recent launches. However, there are also concerns about potential headwinds from generic compe